Catabasis hopes to ride Sarepta approval wave

Several weeks after winning approval for eteplirsen, the Cambridge-based company is teaming up with another biotech down the street to test a combo therapy in DMD.

By Lisa LaMotta • Sept. 29, 2016

Evotec inks deal with C4X Discovery

The drug discovery companies aim to collaboratively develop drugs targeting cancer and autoimmune diseases.

By Joe Cantlupe • Sept. 29, 2016

Oncodesign snaps up GSK French research center

The British pharma is shedding research facilities as it refocuses resources to key therapeutics areas. 

By Suzanne Elvidge • Sept. 29, 2016

Genentech commits $80M upfront in Hanmi licensing deal

The Roche subsidiary will have sole rights to commercialize Hanmi’s tumor-suppressing drug outside of South Korea.

By Jacob Bell • Sept. 29, 2016

As Repatha flounders, Amgen bolsters CV pipeline

With its PCSK9 inhibitor still flailing, the big biotech added two RNA interference drugs in a licensing deal with Arrowhead Pharmaceuticals. 

By Lisa LaMotta • Sept. 29, 2016

Small cancer biotech Tracon secures licensing pact with J&J

The deal gives Tracon $5M in equity and access to two preclinical oncology assets to bump up its early-stage pipeline.

By Suzanne Elvidge • Sept. 29, 2016

Athenex and SunGen seal deal for US market

The joint venture, which has the companies working together to launch and market seven drugs, is one of several it has planned for the near term.

By Joe Cantlupe • Sept. 28, 2016

Suitors circle as Bayer considers asset sale: report

Mylan and Lupin are among a number of drugmakers reportedly lining up to buy Bayer's dermatology business, according to Bloomberg.   

By Joe Cantlupe • Sept. 28, 2016

Shire pulls out of biosimilar development

Two Phase 3 biosimilars were returned to development partners as Shire reevaluates Baxalta assets to focus further on rare diseases. 

By Suzanne Elvidge • Sept. 28, 2016

Bayer, Evotec ink research pact for kidney disease

Bayer's second research deal with Evotec could be worth as much as €300 million if certain milestones are hit. 

By Suzanne Elvidge • Sept. 23, 2016

Sonoco ThermoSafe buys Laminar Medica

The Illinois-based packing provider will acquire the UK-based pallet shipping producer to strengthen its shipping capabilities for biopharma companies.  

By Joe Cantlupe • Sept. 22, 2016

Genentech, BioNTech team up on cancer vaccines

Roche's cancer unit will pay a hefty $310 million upfront to access the German biotech's mRNA platform technology. 

By Lisa LaMotta • Sept. 22, 2016

PCT spears a cancer deal with Adaptimmune

The new agreement expands an existing collaboration between the two companies, and will cover cancer immunotherapy manufacturing. 

By Suzanne Elvidge • Sept. 22, 2016

Momenta, BioFactura team up on biosimilars

With a number of aging, yet still top-selling, biologics nearing patent expiry, biosimilar development in the U.S. is gaining steam. 

By Suzanne Elvidge • Sept. 22, 2016

Eleven Bio gets cancer focused with Viventia

A Phase 3 miss earlier this year led to major cutbacks in staff at Eleven Bio, which now attempts to reinvent itself through Viventia's pipeline. 

By Suzanne Elvidge • Sept. 22, 2016

GSK pledges to drop vax price for refugees

Discounts will apply at first only to Synflorix, the British drugmaker's pneumococcal vaccine. 

By Suzanne Elvidge • Sept. 21, 2016

Regeneron and Teva team up on long-mired painkiller

The biotech inks a deal with the Israeli company for its osteoarthritis drug. 

By Joe Cantlupe • Sept. 21, 2016

Allergan makes second acquisition in NASH space

The specialty pharma adds to its pipeline with back-to-back deals.

By Lisa LaMotta • Sept. 21, 2016

Madrigal sells off rights to cancer platform

Tarceva Therapeutics lined up milestones worth as much as $163M to secure global rights to Madrigal's drug conjugate program. 

By Suzanne Elvidge • Sept. 20, 2016

Allergan pays steep premium for Tobira and NASH drugs

Despite a recent trial miss for Tobira's lead drug, Allergan will pay six times the biotech's closing price Monday to get into the red-hot NASH space. 

By Ned Pagliarulo • Sept. 20, 2016

Dr Reddy's and Amgen broaden marketing collaboration

Under a 2015 partnership, Dr. Reddy's markets and distributes a number of Amgen drugs in India. An additional three drugs will now be covered by the agreement. 

By Suzanne Elvidge • Sept. 19, 2016

Rigel reorganization slashes 46 jobs

Restructuring the company around fostamatinib will save Rigel money but cost 38% of the workforce.

By Suzanne Elvidge • Sept. 16, 2016

OncoImmune locks up $250M antibody deal with Pfizer

Pfizer continues to build out its cancer portfolio, gaining access to OncoImmune's anti-CTLA4 mAb in a new licensing deal. 

By Suzanne Elvidge • Sept. 16, 2016

Takeda partners with PRA on drug development

About 300 Takeda employees have the option to move downstream to new positions at PRA in the U.S. and Europe. 

By Suzanne Elvidge • Sept. 15, 2016

Bayer lands $66B Monsanto deal

With the massive all-cash acquisition of the U.S. seed giant, the German pharma will significantly expand its agricultural sciences business. 

By Lisa LaMotta • Sept. 15, 2016